Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

152.11 +0.48 (+0.32%)
Official Closing Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
The 7 Biggest Dividend Stocks in Warren Buffett’s Portfolio
Are you curious about those Warren Buffet dividend stocks he owns in his portfolio? This article has you covered on the most important names. 
Via InvestorPlace
Daily Wear Contact Lenses Market May See a Big Move: Major Giants Alcon, Hydron, Lagado Corporation, Metro Optics, Johnson & Johnson Vision Care
According to HTF Market Intelligence, the Global Daily Wear Contact Lenses Market Breakdown by Application (Corrective Lenses, Therapeutic Lenses, Cosmetic Lenses, Lifestyle-Oriented Lenses) by Type... 
Via SBWire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Is NYSE:JNJ suited for dividend investing?
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Market Whales and Their Recent Bets on JNJ Options
Via Benzinga
2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now
With clear advantages over the competition, these divided payers could deliver market-beating gains to patient investors. 
Via The Motley Fool
Google Alum's Biotech Startup Cradle Raises $24M To Boost AI-Powered Protein Design And Engineering
Dutch biotech startup Cradle has raised $24 million in Series A funding as it looks to boost its protein design and engineering process. 
Via Benzinga
3 Robotics Stocks That Could Be Multibaggers in the Making
These robotics stocks all deserve a place in your portfolio. Each company has unique value catalysts which make them worthy of consideration. 
Via InvestorPlace
The Shocking Stock That Warren Buffet Just Bought (and 2 He Sold)
The Oracle of Omaha buys a lot of different companies but the one stock that Warren Buffet just bought may surprise you. 
Via InvestorPlace
5 Stocks You Can Confidently Invest $500 In Right Now
These companies could significantly grow your investment over the long haul. 
Via The Motley Fool
Dividend Aristocrats In Focus: Kenvue
An analysis of Kenvue’s business model, future growth catalysts, and expected returns. 
Via Talk Markets
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
Behind the Scenes of Johnson & Johnson's Latest Options Trends
Via Benzinga
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
These companies offer low-risk growth and income at a value price. 
Via The Motley Fool
Johnson & Johnson and Intuitive Surgical Might Become Ozempic's Next Victims. Are They Still Worth Buying?
With retailers worrying about Ozempic's impact, healthcare stocks could be next. 
Via The Motley Fool
Warren Buffett-Led Berkshire Hathaway Sells Its Entire Procter & Gamble Stake. Should You?
Procter & Gamble has proven it can justify repeated price hikes without overly damaging sales volume. 
Via The Motley Fool
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by... 
Via SBWire
3 Dividend Stocks You Can Safely Hold for Decades
Investors can confidently buy these income stocks for the long term. 
Via The Motley Fool
21 Analysts Have This to Say About Johnson & Johnson
Via Benzinga
Skin Tightening Products Market to Witness Massive Growth by 2029 : L'Oréal, Johnson & Johnson, Amway
Stay up to date with Skin Tightening Products Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Worried About Market Volatility? Invest In These High-Yield Dividend Stocks For Consistent Passive Income
Via Benzinga
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
5 Longtime Holdings Warren Buffett Completely Sold During the Third Quarter
These brand-name companies had been fixtures in Berkshire Hathaway's portfolio for the past 11 to 18 years. 
Via The Motley Fool
Why Is Depression Focused MIRA Pharmaceuticals Stock Trading Higher Today?
MIRA Pharmaceuticals Inc (NASDAQ: MIRA) announced a partnership with MIRALOGX, LLC, an intellectual property holding company  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Stock Market This Week – Sunday, Nov. 19
This past week’s economic reports delivered good news for the U.S. economy and the stock market. Inflation is down a lot. The Consumer Price Index came in flat; the year-over-year reading is 3.2%. Both... 
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
7 High-Yield Blue Chips Suitable for Any Retiree
Here are seven high-yield blue-chip stocks to help you meet your retirement goals no matter where you are on your investment journey. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Johnson & Johnson Resolves 2 Major Talc Cases As Legal Battles Continue
Johnson & Johnson (NYSE: JNJ) announced settlements in two talc-related cases, the news follows an appeals court's ruling which overturned a $223.8 million verdict 
Via Benzinga
Why Warren Buffett, Ray Dalio's Hedge Funds Are Selling Top-Ranking Dividend King
Johnson & Johnson, a top-ranked dividend king, was a popular sell among hedge fund billionaires in Q3. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.